今年8月，新京报曾刊发调查报道，大连富生制药有限公司推出的"富力博士人参皂苷Rg3"刻意暗示具备抗肿瘤功 效，实为固体饮料类普通食品。律师表示，这种行为可能构成《中华人民共和国反不正当竞争法》中的"混淆行 为"。据《中华人民共和国反不正当竞争法》第六条规定，经营者不得实施引人误认为是他人商品或者与他人存在 特定联系的混淆行为。若被认定违法，可根据情节处以罚款，违法所得将被没收。报道刊发后，商家将涉事产品 下架。 时隔数月，记者回访发现，相关产品已重新上架销售。销售页面未再明示功效，但宣传图文中的部分介绍、奖项 等素材，仍与抗癌药物"参一胶囊"关联。 修改部分宣传后再次上架 今年8月19日，新京报刊发《高价人参皂苷食品暗示抗癌功效，富生制药被指虚假宣传》一文，报道了富生网健保 健食品专营店售价达1780元/盒的"富力博士人参皂苷Rg3"产品通过官网、电商页面的"科研成果展示""AI智能解 答"等多种方式，暗示具有抗肿瘤功效，甚至与已获批的抗癌药物"参一胶囊"捆绑，而产品实为固体饮料，属于普 通食品。报道中，面对记者"产品能否抗肿瘤"的咨询，店铺客服未直接回应，而是发送了一张"DeepSeek智能 AI"的对话截 ...

今年8月，新京报曾刊发调查报道，大连富生制药有限公司推出的"富力博士人参皂苷Rg3"刻意暗示具备抗肿瘤功效，实为固体饮料类普通食品。律师表 示，这种行为可能构成《中华人民共和国反不正当竞争法》中的"混淆行为"。据《中华人民共和国反不正当竞争法》第六条规定，经营者不得实施引人误认 为是他人商品或者与他人存在特定联系的混淆行为。若被认定违法，可根据情节处以罚款，违法所得将被没收。报道刊发后，商家将涉事产品下架。 时隔数月，记者回访发现，相关产品已重新上架销售。销售页面未再明示功效，但宣传图文中的部分介绍、奖项等素材，仍与抗癌药物"参一胶囊"关联。 修改部分宣传后再次上架 今年8月19日，新京报刊发《高价人参皂苷食品暗示抗癌功效，富生制药被指虚假宣传》一文，报道了富生网健保健食品专营店售价达1780元/盒的"富力博 士人参皂苷Rg3"产品通过官网、电商页面的"科研成果展示""AI智能解答"等多种方式，暗示具有抗肿瘤功效，甚至与已获批的抗癌药物"参一胶囊"捆绑，而 产品实为固体饮料，属于普通食品。报道中，面对记者"产品能否抗肿瘤"的咨询，店铺客服未直接回应，而是发送了一张"DeepSeek智能AI"的对话截图。截 图 ...

Core Viewpoint - Jilin Yatai Group's 2025 semi-annual report indicates a slight increase in revenue despite ongoing challenges in the construction and real estate sectors, with a focus on optimizing asset structure and reducing debt [1][2]. Company Overview and Financial Indicators - The company reported a revenue of approximately CNY 3.04 billion for the first half of 2025, representing a 3.67% increase compared to the same period last year [2]. - The total profit for the period was approximately -CNY 992 million, an improvement of 13.22% year-on-year [2]. - The net profit attributable to shareholders was approximately -CNY 823 million, showing an 11.27% improvement from the previous year [2]. - The company's net assets decreased by 32.58% to approximately CNY 1.87 billion compared to the end of the previous year [2]. Industry Analysis Construction Materials - The national cement production was 815 million tons, a year-on-year decrease of 4.3%, but the decline rate has narrowed [3]. - The cement industry is experiencing weak demand but improved profitability due to rising prices in Northeast China and decreasing coal prices [3]. Real Estate - Real estate development investment decreased by 11.2%, with new housing starts down by 20.0% and sales area down by 3.5% [3]. - The market is characterized by investment contraction and a narrowing decline in sales, with local policies aimed at stabilizing the market [3]. Pharmaceutical Industry - The pharmaceutical sector is expected to grow due to increasing demand for high-quality medicines driven by economic development and an aging population [3]. - The company has established a comprehensive health management service through its extensive pharmacy network [3]. Operational Discussion - The company is focusing on reducing debt and stabilizing operations while optimizing its asset structure [4]. - In the construction materials sector, the company is collaborating with large enterprises on urban renewal and infrastructure projects [4]. - The real estate sector is prioritizing inventory reduction and cost management, leveraging national policies to accelerate land monetization [4]. Financial Investment - The company holds a 30.81% stake in Northeast Securities and a 6.88% stake in Jilin Bank, focusing on equity management to enhance overall investment returns [7][9].

Core Viewpoint - The company Dalian Fusheng Pharmaceutical is under scrutiny for misleading advertising of its product "Fuli Doctor Ginsenoside Rg3," which is marketed as having anti-tumor effects but is actually a solid beverage and not a drug [1][2][6]. Product Description - The product "Fuli Doctor Ginsenoside Rg3" is sold at a price of 1780 yuan per box and is classified as a solid beverage, containing mainly ginseng roots aged five years or less [1][2]. - The product's composition includes ginsenosides Rg3 and Rg5, with specific amounts stated, but it lacks any unique medicinal ingredients [2][3]. Marketing and Promotion Tactics - The company employs various promotional strategies, including showcasing research achievements and using AI to suggest potential health benefits, which may mislead consumers into believing the product has anti-cancer properties [3][9][14]. - The marketing materials frequently reference the product's association with a drug called "Can Yi Capsule," which has been approved for cancer treatment, creating a misleading connection between the food product and pharmaceutical efficacy [6][26]. Legal and Regulatory Concerns - The promotional practices may violate the Anti-Unfair Competition Law and the Price Law of the People's Republic of China, as they could be seen as misleading consumers regarding the product's capabilities and pricing [6][7][8][26]. - Legal experts indicate that the company's actions could be classified as "confusion behavior," potentially leading to penalties if deemed unlawful [6][26]. Scientific Evidence and Expert Opinions - Experts note that while there is some evidence suggesting ginsenoside Rg3 may have anti-cancer properties, the clinical evidence supporting its efficacy is insufficient, with most studies being small-scale and lacking rigorous design [21][22]. - The product's marketing may lead consumers to mistakenly believe it can replace conventional cancer treatments, which poses significant health risks [25][26].